ADA’s 2022 Hybrid Scientific Sessions delivers the latest scientific advances and groundbreaking research presentations, including HealthCore’s latest findings in diabetes research.
Registration is required to view presentations. For more information, please visit https://professional.diabetes.org/scientific-sessions.
Late Breaking Poster Session
163-LB | Impact of Preexisting Type 2 Diabetes (T2D) and Concurrent Cardiovascular Disease (CVD) on Patients with COVID-19 (C-19)
Nguyen C1, Crowe C1, Kuti E2, Narsipur N2, Donato B2, Pepe R1, Djaraher R1, Seman L2, Graeter N2, Power TP3, Mehra R4, Willey VJ1
1HealthCore, Inc., Wilmington, DE, 2Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, 3AIM Specialty Health, Chicago, IL, 4AmeriGoup, Hanover, MD
General Poster Session
752-P | Study Design and Baseline Profile for Patients with Type 2 Diabetes in the Semaglutide Once-Weekly Randomized Pragmatic Trial (SEPRA)
Willey V1, Buse J2, Harty B1, Mitchell J3, Soule B4, Nordahl H4, Cziraky M1, Skibsted S4
1HealthCore, Inc., Wilmington, DE, 2University of North Carolina, Chappel Hill, NC, 3Anthem, Inc., Indianapolis, IN, 4Novo Nordisk, Plainsboro, NJ
*HealthCore authors are indicated in bold.